| Sarpogrelate Delivered via Osmotic Pump Enhances Residual Hearing Preservation After Cochlear Implantation |
| Jungho Ha1,4, Siung Sung3, Jongmoon Jang2, Young Sun kim1, Seongjun So1, Jeong Hyeon Yun3, Yun-Hoon Choung1,4, Jeong Hun Jang1,4 |
1Department of Otolaryngology, Ajou University School of Medicine, Suwon, Republic of Korea
2Department of Functional Ceramics, Korea Institute of Materials Science (KIMS), Changwon, Republic of Korea
3Department of Biomedical Science, Ajou University Graduate School of Medicine, Suwon 16499, Republic of Korea
4Department of Medical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea |
| Correspondence |
Jeong Hun Jang ,Tel: +82 53 200 5783, Fax: +82 53 424 45, Email: jhj@ajou.ac.kr
|
|
Received: December 6, 2024; Revised: March 2, 2025 Accepted: March 16, 2025. Published online: March 17, 2025.
*Jungho Ha and Siung Sung contributed equally to this work. |
|
|
|
| ABSTRACT |
Objective
This study evaluated the effects of sarpogrelate, a selective 5-hydroxytryptamine (5-HT) 2A receptor antagonist, on residual hearing preservation and inflammatory responses after cochlear implantation (CI) in an animal model.
Methods
The damaging effects of CI were simulated in male albino guinea pigs by using a dummy electrode. Animals were divided into three groups: control (n=12, dummy electrode insertion only), SPG-1004 (n=7, low-capacity pump with sarpogrelate), and SPG-2004 (n=6, high-capacity pump with sarpogrelate). Sarpogrelate was administered via osmotic pumps at two different volumes and its effect on hearing thresholds, histological outcomes, and the expression of inflammation-related genes were evaluated. Hearing was evaluated using auditory brainstem response (ABR) thresholds at baseline (preoperatively) and at 1-, 7-, and 30-days postoperatively.
Results
Sarpogrelate administration through an osmotic pump led to significant hearing preservation across all tested frequencies at 1-month post-surgery (p<0.05), as compared with the control group, which only underwent dummy electrode insertion. Histological analysis revealed that cochlear fibrosis and inflammatory cell infiltration were significantly reduced in the sarpogrelate-treated groups, and more so in the group with the higher pump volume. Gene expression analysis supported these findings, showing a significant reduction in inflammationrelated markers in the sarpogrelate-treated groups.
Conclusion
Sarpogrelate demonstrated a protective effect against loss of residual hearing after CI, likely due to its anti-inflammatory and antifibrotic properties. Moreover, the use of an osmotic pump allowed controlled and sustained delivery of the drug over time. These findings suggest that sarpogrelate administered via an osmotic pump is a promising pharmacological approach for improving postoperative outcomes in patients with CI by preserving residual hearing. |
| Keywords:
Cochlear implant, Hearing loss, Residual hearing, Sarpogrelate |
|
|
|
Download PDF File
Full text via DOI
Download Citation 
